Machine learning-driven drug discovery platform founded by Stanford ML pioneer Daphne Koller
Biotech📍 South San Francisco, CAFounded 2018
Current Valuation
$2.4B
as of 2021-Q1
UNICORN
IPO Outlookprivate
Is Insitro going public?
No. Insitro has no imminent IPO plans on record. It is still private.
What is Insitro's valuation in 2026?
Insitro is valued at $2.4B as of 2021-Q1, set by its Series C ($400M, Mar 2021). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Insitro filed an S-1?
No public S-1 is on file for Insitro.
Who are Insitro's investors?
Insitro's investors include Canada Pension Plan Investment Board, Andreessen Horowitz, ARCH Venture Partners, Foresite Capital, GV, T. Rowe Price and 2 more.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Insitro applies machine learning to generate and analyze human disease models, identifying drug targets that traditional pharma misses. Founded by Daphne Koller (Coursera co-founder, ex-Stanford CS / Calico chief computing officer). Pipeline partnerships with BMS and Gilead worth $2B+ in milestones. CPP Investment Board-led Series C valued the company at $2.4B in 2021.
Company Profile
CEO
Daphne Koller
Founded
2018
HQ
South San Francisco, CA
Employees
~250
Total Raised
$743M
Growth
Pre-revenue (collaboration milestones)
Last Round
Series C — $400M (Mar 2021) · Lead: Canada Pension Plan Investment Board
IPO Status
no imminent plans
Fundraising Status
Series C · $400M · 5y 5mo ago
no imminent plansTotal raised $743M
Secondary Market
Implied price / share
$12.94
Last round price / share
$18.29
vs last round
-29.3%
Last round price vs secondary price
Secondary price return by period
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series C
$400M
Mar 2021
Canada Pension Plan Investment Board
—
Vertical Intelligence — Biotech / Gene Therapy
No name-verified sponsor record on ClinicalTrials.gov for Insitro — trials may run under a different legal entity, a partner sponsor, or not yet exist. Absence of a registry match is reported as-is, never guessed around.
Checked clinicaltrials.gov as of 2026-08-19. Re-checked weekly.
Talent Signal
Hiring trend
● First snapshot
trend accrues with monthly sweeps
Open roles
14
via ashby
Product-build share
50%
engineering, research, product, design
Trajectory
steady
product-led hiring — 50% of open roles build product; the rest are go-to-market and G&A.
Actively hiring with no tracked executive churn.
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
Senior Machine Learning Scientist, Imaging(Senior) ML ScientistScientist II, Arrayed ScreeningChief Medical OfficerSenior Manager, Imaging Machine LearningSenior Scientist, Cardiac Modeling
Counted from Insitro's live job board as of 2026-08-17; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Founders & Key People
Daphne Koller
Investors
Canada Pension Plan Investment Board · Andreessen Horowitz · ARCH Venture Partners · Foresite Capital · GV · T. Rowe Price · Bezos Expeditions · Casdin Capital
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2021-Q1. Refreshed quarterly.